{"id":"aerosolized-calfactant","safety":{"commonSideEffects":[{"rate":null,"effect":"Transient oxygen desaturation"},{"rate":null,"effect":"Airway obstruction"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Reflux"}]},"_chembl":{"chemblId":"CHEMBL1201447","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Calfactant is a natural lung surfactant derived from calf lung tissue that reduces surface tension in the alveoli, preventing alveolar collapse and improving lung compliance. When delivered as an aerosolized formulation, it reaches distal airways and alveoli to restore surfactant deficiency or dysfunction in respiratory conditions. This mechanism helps restore normal respiratory mechanics and oxygenation.","oneSentence":"Aerosolized calfactant is a pulmonary surfactant replacement therapy delivered directly to the lungs via inhalation to restore surfactant function and improve gas exchange.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:01.753Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute respiratory distress syndrome (ARDS)"},{"name":"Respiratory distress in premature infants (potential)"}]},"trialDetails":[{"nctId":"NCT03058666","phase":"PHASE3","title":"Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients","status":"COMPLETED","sponsor":"ONY","startDate":"2017-03-29","conditions":"Respiratory Distress Syndrome","enrollment":477},{"nctId":"NCT03582930","phase":"","title":"Aerosolized Infasurf Treatment Protocol: Aerosolized Infasurf for Spontaneously Breathing Patients With Early RDS (AERO-03)","status":"NO_LONGER_AVAILABLE","sponsor":"ONY","startDate":"","conditions":"Neonatal Respiratory Distress","enrollment":""},{"nctId":"NCT03748173","phase":"PHASE1","title":"Infasurf®(Calfactant) Aerosol for Infants With Bronchiolitis-AERO-04","status":"TERMINATED","sponsor":"ONY","startDate":"2019-01-12","conditions":"Bronchiolitis","enrollment":13}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Infasurf","Calfactant"],"phase":"phase_3","status":"active","brandName":"Aerosolized Calfactant","genericName":"Aerosolized Calfactant","companyName":"ONY","companyId":"ony","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aerosolized calfactant is a pulmonary surfactant replacement therapy delivered directly to the lungs via inhalation to restore surfactant function and improve gas exchange. Used for Acute respiratory distress syndrome (ARDS), Respiratory distress in premature infants (potential).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}